A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors

Aghanejad, Ayuob; Bonab, Samad Farashi; Sepehri, Maryam; Haghighi, Fatemeh; Tarighatnia, Ali; Kreiter, Christopher; Nader, Nader D.; Tohidkia, Mohammad Reza

doi:10.1016/j.ijbiomac.2022.03.057

Cited by 51 publications

(11 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer immunotherapy has revolutionized cancer treatment both as monotherapy or in combination strategies, especially ICIs that block cytotoxic T lymphocyte‐associated protein‐4 (CTLA‐4) and the PD‐1/PD‐L1 axis 39,40 . Immunotherapy is mechanistically different from other treatment modalities that can target the TME and the tumor itself 41 . However, the response rate to ICIs is still far from satisfactory.…”

Section: Discussionmentioning

confidence: 99%

Perspectives for immunotherapy of EBV‐associated GLELC: A relatively “hot” tumor microenvironment

Lei,

Cao,

Zheng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundEpstein–Barr virus (EBV)‐associated gastric lymphoepithelioma‐like carcinoma (EBVaGLELC) represents a small number of gastric cancer (GC), and research on tumor microenvironment (TME) and treatment strategy are still lacking.AimsHere, we aim to elucidate the immune features of this rare disease and further help to develop more effective treatment options.Materials & MethodsA retrospective analysis was conducted between 2019 to 2022 in West China Hospital to reveal the immunological characteristics of EBV‐positive GLELC. The difference of immune cell subset and tumor vascular structure between gastric denocarcinoma (GAC) and EBVaGLELC will be pointed out.Discussion13 patients with GELEC and 8 patients with GAC were retrospectively studied. The heterogeneity of the immune cell profile was then confirmed through multiplexed immunofluorescence staining (mIF), which revealed a higher proportion of CD3+ T cells, CD8+ T cells, and Treg cells in the EBV‐associated GLELC group. Such a distinct TME may provide therapeutic advantages, and patients with this rare subtype of GC could be good candidates for immune checkpoint inhibitors (ICIs). Angiogenesis in EBV‐positive GLELC may be less intense than that in gastric adenocarcinoma (GAC), a feature that might decrease their susceptibility to antiangiogenic therapy. Furthermore, we reported a 52‐year‐old male with advanced EBV‐positive GLELC who showed a favorable response to the combined therapy with . A repeat evaluation showed sustained partial response (PR), and the progression‐free survival (PFS) was more than 34 months until now.ConclusionCompared with GAC, EBVaGLELC revealed higher T cell infiltration and less intense of angiogenesis. It displays relatively “hot” TME that may provide the rationality to treat with immunotherapy in EBV‐related GLELC.

show abstract

Section: Discussionmentioning

confidence: 99%

Perspectives for immunotherapy of EBV‐associated GLELC: A relatively “hot” tumor microenvironment

Lei,

Cao,

Zheng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Several anti-PD-1 and anti- PD-L1 antibodies have been developed for immunotherapy of melanoma, lung, bladder, skin, and uterus cancers. Clinical results demonstrated that anti-PD-1 mAbs were more successful than anti-CTLA4 mAbs in patients with advanced-stage melanoma [ 40 ]. Also, several clinical trials are currently employing anti-PD-1 mAbs in the combination of other antibodies (anti-PD-L1, anti-CTLA4, anti-TIM-3, anti-LAG-3, and anti-TGF-β1 mAbs) in various solid tumor models to overcome the resistance to anti-checkpoint immunotherapies [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

et al. 2022

View full text Add to dashboard Cite

Background The PD-1 checkpoint pathway plays a major role in tumor immune evasion and the development of the tumor microenvironment. Clinical studies show that therapeutic antibodies blocking the PD-1 pathway can restore anti-tumor or anti-virus immune responses by the reinvigoration of exhausted T cells. Because of the promising results of anti-PD-1 monoclonal antibodies in cancer treatment, autoimmune disorders, and infectious diseases, the PD-1 has emerged as an encouraging target for different diseases. Results In the present study, we employed a human semi-synthetic phage library for isolation of some scFvs against the extracellular domain of PD-1 protein by panning process. After the panning, a novel anti-PD-1 scFv (SS107) was found that exhibited specific binding to PD-1 antigen and stimulated Jurkat T cells. The selected anti-PD-1 scFv could restore the production of IL-2 and IFN-γ by Jurkat T cells that were co-cultured with PD-L1 positive tumor cells. Conclusion This anti-PD-1 scFv with high specificity and the ability to reactivate exhausted T cells has the potential to be developed as an anti-cancer agent or to be used in combination with other therapeutic approaches.

show abstract

“…3,4 For instance, monoclonal antibodies targeting specific proteins on cancer cells can effectively block or modulate cancerpromoting signals, leading to improved patient outcomes. 5,6 Ribonuclease A (RNase A) is a naturally occurring protein that has gained significant attention in the field of protein therapy, [7][8][9] as it can specifically recognize and bind to the abnormal RNA structure and further cleave the dysregulated RNA molecules to induce the apoptosis of cancer cells. 10 Thus, RNase A possesses selective cytotoxicity towards cancer cells while sparing normal cells, making it an attractive candidate for targeted cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Ribonuclease A–polymer conjugates via in situ growth for cancer treatment

Jiang,

Liang,

Jia

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors

Cited by 51 publications

References 125 publications

Perspectives for immunotherapy of EBV‐associated GLELC: A relatively “hot” tumor microenvironment

Perspectives for immunotherapy of EBV‐associated GLELC: A relatively “hot” tumor microenvironment

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

Ribonuclease A–polymer conjugates via in situ growth for cancer treatment

Contact Info

Product

Resources

About